全球低磷血症治疗市场 – 行业趋势及 2030 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

全球低磷血症治疗市场 – 行业趋势及 2030 年预测

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 页面
  • 桌子數: 220
  • 图号: 60

Global Hypophosphatemia Treatment Market

市场规模(十亿美元)

CAGR :  % Diagram

Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 25.70 Million
Diagram Market Size (Forecast Year)
USD 37.97 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Kyowa Kirin Co
  • Smith+Nephew
  • Nestle
  • Pfizer
  • Koninklijke Philips

全球低磷血症治疗市场,按治疗(药物、外科、骨科)、最终用户(医院、家庭护理、专科诊所、其他)、分销渠道(医院药房、网上药房、零售药房)划分 - 行业趋势和预测到 2030 年。

低磷血症治疗市场

低磷血症治疗市场分析和规模

根据 FDA 2017 年公布的统计数据,美国约有 3,000 名儿童和 12,000 名成人患有低磷血症。这种疾病通常发生在儿童身上,症状包括腿弯曲或罗圈腿、严重的牙齿和骨骼疼痛以及身材矮小。根据美国国家生物技术信息中心 (NCBI) 的数据,在美国,每年约有 11-15% 的人口被诊断出患有高磷血症,其中大多数人患有糖尿病和心血管疾病。这些人患低磷血症的风险很高。

Data Bridge Market Research 分析了 2023-2030 年预测期内低磷血症治疗市场的增长率。在上述预测期内,低磷血症治疗市场的预期复合年增长率趋于 5% 左右。2022 年市场价值为 2570 万美元,到 2030 年将增长至 3797 万美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外,Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

低磷血症治疗市场范围和细分

报告指标

细节

预测期

2023 至 2030 年

基准年

2022

历史岁月

2021(可定制为 2015 - 2020)

定量单位

收入(单位:十亿美元)、销量(单位:台)、定价(美元)

涵盖的领域

治疗(药物、外科、骨科)、最终用户(医院、家庭护理、专科诊所、其他)、分销渠道(医院药房、网上药房、零售药房)

覆盖国家

北美洲的美国、加拿大和墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲其他地区

涵盖的市场参与者

协和麒麟株式会社(日本)、史密斯+侄子(英国)、雀巢(瑞士)、辉瑞公司(美国)、荷兰皇家飞利浦公司(荷兰)、ADM 动物营养公司(美国)、Ultragenyx 制药公司(美国)、南京健友生化制药有限公司(中国)、礼来公司(美国)、F. Hoffmann-La Roche Ltd(瑞士)、Prospec-Tany Technogene Ltd(以色列)

Market Opportunities

  • Rise in elderly population

Market Definition

Hyperphosphatemia is a type of condition in which an abnormal amount of phosphate is present in the blood. The abnormal amount of phosphate is typically witnessed in the population with chronic kidney disease and cardiovascular diseases. In patients suffering from chronic kidney diseases, hyperphosphatemia is a primary cause of mortality and morbidity. The abnormal level of phosphates in hypophosphatemia causes numerous complications in the body including bone pain, bone fractures, appetite loss and confusion.

Global Hypophosphatemia Treatment Market Dynamics

Drivers

  • Increase R&D Activities

The increased R&D activities on hypophosphatemia causes the market to flourish. To overcome the burden of hyperphosphatemia, many treatment options have been studied and research has been carried out. Many phosphate-lowering hyperphosphatemia treatment approaches have been executed to manage and prevent hyperphosphatemia. This boosts the growth of the market.

  • Rising Healthcare Expenditure

The increasing research funding towards several rare diseases such as X-Linked Hypophosphatemia (XLH) and the high healthcare expenditure is also projected to increase the growth of the market during the forecast period. For instance, Genome Canada and the Canadian Institutes for Health Research entered into a partnership to study rare genetic diseases by using Next-Generation Sequencing (NGS) technology. Thus, this factor has impacted in a huge growth of the market.

Opportunities

  • Increase in Elderly Population

The market is estimated to witness a heavy growth rate in the forecast period driven by the factor of an aging population. The increasing demand in the market is the replication of increasing elderly population, as people aged over 60 years often develop low immunity conditions affecting the normal functioning. This boost the market growth.

Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified healthcare professional unable to perform the treatments could reduce the growth of the hypophosphatemia treatment market during the forecast period.

  • Side-Effects of Hypophosphatemia Treatment

The adverse side-effects associated with the treatment process hinder the market growth. Effects such as hearing loss, infections and also some drugs can lead to autoimmune reactions.

本低磷血症治疗市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响,分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需了解有关低磷血症治疗市场的更多信息,请联系 Data Bridge Market Research 获取分析师简报,我们的团队将帮助您做出明智的市场决策,实现市场增长。

全球低磷血症治疗市场范围

低磷血症治疗市场根据治疗、分销渠道和最终用户进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场,并为用户提供有价值的市场概览和市场洞察,帮助他们做出战略决策,确定核心市场应用。

治疗

  • 药物
  • 外科
  • 骨科

最终用户

  • 医院
  • 家庭护理
  • 专科诊所
  • 其他的

分销渠道

  • 医院药房
  • 网上药店
  • 零售药店

低磷血症治疗市场区域分析/见解

对低磷血症治疗市场进行了分析,并按上述治疗、分销渠道和最终用户提供了市场规模洞察和趋势。

低磷血症治疗市场报告涉及的主要国家 有:北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区(APAC)的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区(APAC)的其他地区、中东和非洲(MEA)的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于产品主要制造商的存在感强以及研发活动的不断增加,北美在整个预测期内一直见证着低磷血症治疗市场的积极增长。

由于新研究和开发的增加,亚太地区占据了市场主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外,在提供国家数据预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球低磷血症治疗市场份额分析

低磷血症治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对低磷血症治疗市场的关注有关。

低磷血症治疗市场的主要参与者包括:

  • 协和麒麟株式会社(日本
  • Smith+Nephew(英国)
  • 雀巢(瑞士)
  • 辉瑞公司(美国)
  • Koninklijke Philips NV(荷兰)
  • ADM 动物营养(美国)
  • Ultragenyx Pharmaceutical(美国)
  • 南京健友生化药业有限公司 (中国)
  • 礼来(美国)
  • F. Hoffmann-La Roche Ltd(瑞士)
  • Prospec-Tany Technogene Ltd(以色列)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market is segmented based on , By Treatment (Medication, Surgical, Orthopaedic), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030. .
The Global Hypophosphatemia Treatment Market size was valued at USD 25.70 USD Million in 2022.
The Global Hypophosphatemia Treatment Market is projected to grow at a CAGR of 5% during the forecast period of 2023 to 2030.
The major players operating in the market include Kyowa Kirin Co, Smith+Nephew, Nestle, Pfizer, Koninklijke Philips, ADM Animal Nutrition, Ultragenyx Pharmaceutical, Nanjing Jianyou Biochemical Pharmaceutical Co, Lilly, F. Hoffmann La Roche, Prospec, Tany Technogene Ltd.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.